Low-Dose Alteplase versus Conventional Anticoagulation to treat Submassive Pulmonary Embolism in Hispanic Patients.
Hispanic
anticoagulation
hemodynamics
length of stay
low-dose alteplase
pulmonary embolism
tissue plasminogen activator
Journal
The International journal of angiology : official publication of the International College of Angiology, Inc
ISSN: 1061-1711
Titre abrégé: Int J Angiol
Pays: United States
ID NLM: 9504821
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
19
5
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
epublish
Résumé
The use of low-dose tissue plasminogen activator (tPA) in Hispanic patients with submassive pulmonary embolism (PE) is understudied. The purpose of this study is to explore the use of low-dose tPA in Hispanic patients with submissive PE compared with counterparts that received heparin alone. We retrospectively analyzed a single-center registry of patients with acute PE between 2016 and 2022. Out of 72 patients admitted for acute PE and cor pulmonale, we identified six patients that were treated with conventional anticoagulation (heparin alone) and six patients who received low-dose tPA (and heparin afterward). We analyzed if low-dose tPA was associated with differences in length of stay (LOS) and bleeding complications. Both groups were similar in regard to age, gender, and PE severity (based on Pulmonary Embolism Severity Index scores). Mean total LOS for the low-dose tPA group was 5.3 days, compared with 7.3 days in the heparin group (
Identifiants
pubmed: 37207012
doi: 10.1055/s-0042-1758386
pii: ija-2022-0055
pmc: PMC10191688
doi:
Types de publication
Journal Article
Langues
eng
Pagination
131-135Informations de copyright
International College of Angiology. This article is published by Thieme.
Déclaration de conflit d'intérêts
Conflicts of Interest None declared.
Références
Neurology. 2006 Jan 10;66(1):30-4
pubmed: 16401841
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
J Vasc Interv Radiol. 2015 Jul;26(7):1001-6
pubmed: 25704224
Circulation. 2011 Apr 26;123(16):1788-830
pubmed: 21422387
N Engl J Med. 2014 Apr 10;370(15):1402-11
pubmed: 24716681
Anadolu Kardiyol Derg. 2014 Jun;14(4):400-2
pubmed: 24818973
Anesth Analg. 2011 Feb;112(2):319-21
pubmed: 21127275
Circulation. 2011 May 24;123(20):2219-25
pubmed: 21555707
Chest. 2021 Dec;160(6):2247-2259
pubmed: 34352279
Pharmacotherapy. 2014 Aug;34(8):818-25
pubmed: 24854996
Thromb Res. 2014 Mar;133(3):357-63
pubmed: 24412030
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Chest. 2010 Feb;137(2):254-62
pubmed: 19741062
Am J Med. 2011 Jan;124(1):48-57
pubmed: 21187185
Am J Cardiol. 2013 Jan 15;111(2):273-7
pubmed: 23102885
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619853037
pubmed: 31185730
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
JAMA. 2014 Jun 18;311(23):2414-21
pubmed: 24938564
Neurology. 2008 Sep 2;71(10):731-5
pubmed: 18550859
Circulation. 2004 Aug 10;110(6):744-9
pubmed: 15262836
Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1219-27
pubmed: 26308961
J Thromb Haemost. 2014 Apr;12(4):459-68
pubmed: 24484241
Crit Care Med. 2018 Oct;46(10):1617-1625
pubmed: 29979222
Thromb Haemost. 2021 Jun;121(6):816-825
pubmed: 33423245
Am J Med. 2012 May;125(5):465-70
pubmed: 22325236
Am J Respir Crit Care Med. 2005 Oct 15;172(8):1041-6
pubmed: 16020800
Circulation. 1997 Jun 3;95(11):2508-16
pubmed: 9184581
Circulation. 1991 Jan;83(1):170-5
pubmed: 1898641
Cochrane Database Syst Rev. 2017 Feb 09;2:CD001100
pubmed: 28182249